Immunomodulatory Treatment Impact on IVF Outcomes in KIR AA Genotype: Personalized Fertility Insights
Abstract
:1. Introduction
2. Materials and Methods
2.1. Embryo Transfer Preparation
2.2. Statistical Analysis
3. Results
3.1. Baseline Characteristics of Groups
3.2. Descriptive Statistics Group A and Group B
3.3. Comparation of Parameters for Group A and Group B
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ma, J.; Gao, W.; Li, D. Recurrent implantation failure: A comprehensive summary from etiology to treatment. Front. Endocrinol. 2023, 13, 1061766. [Google Scholar] [CrossRef] [PubMed]
- Fukui, A.; Yokota, M.; Funamizu, A.; Nakamua, R.; Fukuhara, R.; Yamada, K.; Kimura, H.; Fukuyama, A.; Kamoi, M.; Tanaka, K.; et al. Changes of NK Cells in Preeclampsia. Am. J. Reprod. Immunol. 2012, 67, 278–286. [Google Scholar] [CrossRef] [PubMed]
- Wasilewska, A.; Grabowska, M.; Moskalik-Kierat, D.; Brzoza, M.; Laudański, P.; Garley, M. Immunological Aspects of Infertility—The Role of KIR Receptors and HLA-C Antigen. Cells 2024, 13, 59. [Google Scholar] [CrossRef] [PubMed]
- Hiby, S.E.; Walker, J.J.; O’Shaughnessy, K.M.; Redman, C.W.; Carrington, M.; Trowsdale, J.; Moffett, A. Combinations of Maternal KIR and Fetal HLA-C Genes Influence the Risk of Preeclampsia and Reproductive Success. J. Exp. Med. 2004, 200, 957–965. [Google Scholar] [CrossRef] [PubMed]
- Stefańska, K.; Tomaszewicz, M.; Dębska-Zielkowska, J.; Zamkowska, D.; Piekarska, K.; Sakowska, J.; Studziński, M.; Tymoniuk, B.; Adamski, P.; Jassem-Bobowicz, J.; et al. KIR-Ligand Interactions in Hypertensive Disorders in Pregnancy. Front. Immunol. 2022, 13, 868175. [Google Scholar] [CrossRef] [PubMed]
- Coughlan, C.; Ledger, W.; Wang, Q.; Liu, F.; Demirol, A.; Gurgan, T.; Cutting, R.; Ong, K.; Sallam, H.; Li, T.C. Recurrent implantation failure: Definition and management. Reprod. Biomed. 2014, 28, 14–38. [Google Scholar] [CrossRef] [PubMed]
- Polanski, L.T.; Baumgarten, M.N.; Quenby, S.; Brosens, J.; Campbell, B.K.; Raine-Fenning, N.J. What exactly do we mean by ‘recurrent implantation failure’? A systematic review and opinion. Reprod. Biomed. 2014, 28, 409–423. [Google Scholar] [CrossRef] [PubMed]
- Cimadomo, D.; Santos, M.J.d.L.; Griesinger, G.; Lainas, G.; Le Clef, N.; McLernon, D.J.; Montjean, D.; Toth, B.; Vermeulen, N.; Macklon, N. ESHRE good practice recommendations on recurrent implantation failure. Hum. Reprod. Open 2023, 2023, hoad023. [Google Scholar] [CrossRef] [PubMed]
- Hiby, S.E.; Apps, R.; Sharkey, A.M.; Farrell, L.E.; Gardner, L.; Mulder, A.; Claas, F.H.; Walker, J.J.; Redman, C.C.; Morgan, L.; et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J. Clin. Investig. 2010, 120, 4102–4110. [Google Scholar] [CrossRef]
- Faridi, R.M.; Agrawal, S. Killer immunoglobulin-like receptors (KIRs) and HLA-C allorecognition patterns implicative of dominant activation of natural killer cells contribute to recurrent miscarriages. Hum. Reprod. 2011, 26, 491–497. [Google Scholar] [CrossRef]
- Traherne, J.A.; Martin, M.; Ward, R.; Ohashi, M.; Pellett, F.; Gladman, D.; Middleton, D.; Carrington, M.; Trowsdale, J. Mechanisms of copy number variation and hybrid gene formation in the KIR immune gene complex. Hum. Mol. Genet. 2010, 19, 737–751. [Google Scholar] [CrossRef] [PubMed]
- Colucci, F. The role of KIR and HLA interactions in pregnancy complications. Immunogenetics 2017, 69, 557–565. [Google Scholar] [CrossRef] [PubMed]
- Jiang, W.; Johnson, C.; Jayaraman, J.; Simecek, N.; Noble, J.; Moffatt, M.F.; Cookson, W.O.; Trowsdale, J.; Traherne, J.A. Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors. Genome Res. 2012, 22, 1845–1854. [Google Scholar] [CrossRef] [PubMed]
- Piekarska, K.; Radwan, P.; Tarnowska, A.; Wiśniewski, A.; Radwan, M.; Wilczyński, J.R.; Malinowski, A.; Nowak, I. ERAP, KIR, and HLA-C Profile in Recurrent Implantation Failure. Front. Immunol. 2021, 12, 755624. [Google Scholar] [CrossRef] [PubMed]
- Pyo, C.-W.; Guethlein, L.A.; Vu, Q.; Wang, R.; Abi-Rached, L.; Norman, P.J.; Marsh, S.G.E.; Miller, J.S.; Parham, P.; Geraghty, D.E. Different Patterns of Evolution in the Centromeric and Telomeric Regions of Group A and B Haplotypes of the Human Killer Cell Ig-Like Receptor Locus. PLoS ONE 2010, 5, e15115. [Google Scholar] [CrossRef] [PubMed]
- Gendzekhadze, K.; Norman, P.J.; Abi-Rached, L.; Graef, T.; Moesta, A.K.; Layrisse, Z.; Parham, P. Co-Evolution of KIR2DL3 with HLA-C in a Human Population Retaining Minimal Essential Diversity of KIR and HLA Class I Ligands. Proc. Natl. Acad. Sci. USA 2009, 106, 18692–18697. [Google Scholar] [CrossRef] [PubMed]
- Parham, P.; Moffett, A. Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat. Rev. Immunol. 2013, 13, 133–144. [Google Scholar] [CrossRef] [PubMed]
- Bastu, E.; Demiral, I.; Gunel, T.; Ulgen, E.; Gumusoglu, E.; Hosseini, M.K.; Sezerman, U.; Buyru, F.; Yeh, J. Potential Marker Pathways in the Endometrium That May Cause Recurrent Implantation Failure. Reprod. Sci. 2019, 26, 879–890. [Google Scholar] [CrossRef] [PubMed]
- Donoghue, J.F.; Paiva, P.; Teh, W.T.; Cann, L.M.; Nowell, C.; Rees, H.; Bittinger, S.; Obers, V.; Bulmer, J.N.; Stern, C.; et al. Endometrial uNK cell counts do not predict successful implantation in an IVF population. Hum. Reprod. 2019, 34, 2456–2466. [Google Scholar] [CrossRef]
- Alecsandru, D.; Barrio, A.; Garrido, N.; Aparicio, P.; Pellicer, A.; Moffett, A.; García-Velasco, J.A. Parental human leukocyte antigen-C allotypes are predictive of live birth rate and risk of poor placentation in assisted reproductive treatment. Fertil. Steril. 2020, 114, 809–817. [Google Scholar] [CrossRef]
- Shapiro, B.S.; Daneshmand, S.T.; Desai, J.; Garner, F.C.; Aguirre, M.; Hudson, C. The risk of embryo-endometrium asynchrony increases with maternal age after ovarian stimulation and IVF. Reprod. Biomed. 2016, 33, 50–55. [Google Scholar] [CrossRef] [PubMed]
- Polanski, L.T.; Barbosa, M.A.P.; Martins, W.P.; Baumgarten, M.N.; Campbell, B.; Brosens, J.; Quenby, S.; Raine-Fenning, N. Interventions to improve reproductive outcomes in women with elevated natural killer cells undergoing assisted reproduction techniques: A systematic review of literature. Hum. Reprod. 2014, 29, 65–75. [Google Scholar] [CrossRef] [PubMed]
- Velikova, T.; Sekulovski, M.; Bogdanova, S.; Vasilev, G.; Peshevska-Sekulovska, M.; Miteva, D.; Georgiev, T. Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine. Antibodies 2023, 12, 20. [Google Scholar] [CrossRef] [PubMed]
- Chazara, O.; Xiong, S.; Moffett, A. Maternal KIR and fetal HLA-C: A fine balance. J. Leukoc. Biol. 2011, 90, 703–716. [Google Scholar] [CrossRef]
- Moffett, A.; Colucci, F. Co--evolution of NK receptors and HLA ligands in humans is driven by reproduction. Immunol. Rev. 2015, 267, 283–297. [Google Scholar] [CrossRef] [PubMed]
- Quenby, S.; Nik, H.; Innes, B.; Lash, G.; Turner, M.; Drury, J.; Bulmer, J. Uterine natural killer cells and angiogenesis in recurrent reproductive failure. Hum. Reprod. 2009, 24, 45–54. [Google Scholar] [CrossRef] [PubMed]
- Seshadri, S.; Sunkara, S.K. Natural killer cells in female infertility and recurrent miscarriage: A systematic review and meta-analysis. Hum. Reprod. Updat. 2014, 20, 429–438. [Google Scholar] [CrossRef] [PubMed]
- (The Writing Group) for the Participants to the 2022 Lugano RIF Workshop; Pirtea, P.; Cedars, M.I.; Devine, K.; Ata, B.; Franasiak, J.; Racowsky, C.; Toner, J.; Scott, R.T.; de Ziegler, D.; et al. Recurrent implantation failure: Reality or a statistical mirage?: Consensus statement from the July 1, 2022 Lugano Workshop on recurrent implantation failure. Fertil. Steril. 2023, 120, 45–59. [Google Scholar] [CrossRef]
- Gil Laborda, R.; de Frías, E.R.; Subhi-Issa, N.; de Albornoz, E.C.; Meliá, E.; Órdenes, M.; Verdú, V.; Vidal, J.; Suárez, E.; Santillán, I.; et al. Centromeric AA motif in KIR as an optimal surrogate marker for precision definition of alloimmune reproductive failure. Sci. Rep. 2024, 14, 3354. [Google Scholar] [CrossRef]
- Practice Committee of the American Society for Reproductive Medicine. The role of immunotherapy in in vitro fertilization: A guideline. Fertil. Steril. 2018, 110, 387–400. [Google Scholar] [CrossRef]
- Sun, Y.; Cui, L.; Lu, Y.; Tan, J.; Dong, X.; Ni, T.; Yan, J.; Guan, Y.; Hao, G.; Liu, J.Y.; et al. Prednisone vs Placebo and Live Birth in Patients with Recurrent Implantation Failure Undergoing In Vitro Fertilization: A Randomized Clinical Trial. JAMA 2023, 329, 1460–1468. [Google Scholar] [CrossRef]
- Nakagawa, K.; Kwak-Kim, J.; Ota, K.; Kuroda, K.; Hisano, M.; Sugiyama, R.; Yamaguchi, K. Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios. Am. J. Reprod. Immunol. 2015, 73, 53–61. [Google Scholar] [CrossRef]
- Maftei, R.; Doroftei, B.; Popa, R.; Harabor, V.; Adam, A.M.; Popa, C.; Harabor, A.; Adam, G.; Nechita, A.; Vasilache, I.A.; et al. The Influence of Maternal KIR Haplotype on the Reproductive Outcomes after Single Embryo Transfer in IVF Cycles in Patients with Recurrent Pregnancy Loss and Implantation Failure—A Single Center Experience. J. Clin. Med. 2023, 12, 1905. [Google Scholar] [CrossRef]
- Hisano, M.; Nakagawa, K.; Kwak-Kim, J.; Sugiyama, R.; Sago, H.; Yamaguchi, K. Changes in the T-helper 1 and 2 cell populations during pregnancy in tacrolimus-treated women with repeated implantation failure and recurrent pregnancy loss. Hum. Fertil. 2022, 25, 975–982. [Google Scholar] [CrossRef]
- Andreescu, M. The impact of the use of immunosuppressive treatment after an embryo transfer in increasing the rate of live birth. Front. Med. 2023, 10, 1167876. [Google Scholar] [CrossRef]
- Alecsandru, D.; Garrido, N.; Vicario, J.L.; Barrio, A.; Aparicio, P.; Requena, A.; Garcia-Velasco, J.A. Maternal KIR haplotype influences live birth rate after double embryo transfer in IVF cycles in patients with recurrent miscarriages and implantation failure. Hum. Reprod. 2014, 29, 2637–2643. [Google Scholar] [CrossRef]
- Morin, S.J.; Treff, N.R.; Tao, X.; Scott, R.T.; Franasiak, J.M.; Juneau, C.R.; Maguire, M. Combination of uterine natural killer cell immunoglobulin receptor haplotype and trophoblastic HLA-C ligand influences the risk of pregnancy loss: A retrospective cohort analysis of direct embryo genotyping data from euploid transfers. Fertil. Steril. 2017, 107, 677–683.e2. [Google Scholar] [CrossRef] [PubMed]
- Luo, Z.; Wang, L.; Wang, Y.; Fan, Y.; Jiang, L.; Xu, X.; Du, Y.; Hao, G. Impact of Insulin Resistance on Ovarian Sensitivity and Pregnancy Outcomes in Patients with Polycystic Ovary Syndrome Undergoing IVF. J. Clin. Med. 2023, 12, 818. [Google Scholar] [CrossRef] [PubMed]
Age | N | Mean | SD | MeanA-B | t | p Value |
---|---|---|---|---|---|---|
Group A | 24 | 35.25 | 5.1659 | −1.36 | 1.0856 | 0.2818 |
Group B | 41 | 36.609 | 4.5685 | |||
Environment | N | Urban | Rural | Mean | SD | p Value |
Group A | 24 | 18 | 6 | 12 | 6 | 0.021 |
Group B | 41 | 37 | 4 | 20.5 | 16.5 | 0.067 |
Number of Oocytes | N | Mean | SD | MeanA-B | t | p Value |
Group A | 24 | 11.125 | 7.1839 | 0.17 | 0.1091 | 0.9134 |
Group B | 41 | 10.95 | 5.3645 |
Characteristics—Group A | Mean | SD |
---|---|---|
HOMA index | 3.586 | 2.674 |
Fertilized oocytes | 7.75 | 5.4 |
Blastocyst | 3.54 | 3.08 |
Blastocyst rate (%) | 47.60 | 23.36 |
No. pregnancy with immunomodulatory treatment | 0.41 | 0.49 |
No. pregnancies without immunomodulatory treatment | 0.166 | 0.372 |
Pregnancy rate (%) with immunomodulatory treatment | 39.58 | 47.82 |
Pregnancy rate (%) without immunomodulatory treatment | 9.375 | 23.73 |
No. ETs with immunomodulatory treatment | 0.958 | 0.538 |
No. ETs without immunomodulatory treatment | 1.458 | 0.9565 |
Characteristics—Group B | Mean | SD |
HOMA index | 2.4036 | 0.748 |
Fertilized oocytes | 8.41 | 4.378 |
Blastocyst | 3.243 | 1.693 |
Blastocyst rate (%) | 40.20 | 10.538 |
No. oocytes | 10.95 | 5.364 |
Pregnancy rate (%) | 34.99 | 35.9859 |
No ETs | 2.658 | 1.117 |
Characteristics—Group A | Mean | SD | MeanA-B | t | p Value |
---|---|---|---|---|---|
Pregnancy rate (%) with immunomodulatory treatment | 39.28 | 47.82 | 0.25 | 1.94 | 0.008 |
Pregnancy rate (%) without immunomodulatory treatment | 9.375 | 23.73 | |||
No. ETs with immunomodulatory treatment | 0.958 | 0.538 | 0.50 | 2.1846 | 0.0041 |
No. ETs without immunomodulatory treatment | 1.458 | 0.9565 |
Characteristics | MeanA-B | SED | t | p Value |
---|---|---|---|---|
HOMA index | −1.824 | 1.858 | 1.858 | 0.9821 |
Fertilized oocytes | −0.66 | 1.253 | 0.5306 | 0.5976 |
Blastocyst | 0.30 | 0.602 | 0.4947 | 0.6225 |
Blastocyst rate (%) | 7.401 | 4.303 | 1.7201 | 0.0090 |
No. ETs | −1.70 | 0.247 | 6.883 | 0.0001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Seles, L.; Zaha, I.A.; Luncan, M.; Bodog, A.; Sachelarie, L.; Sandor, M.; Macovei, I.C.; Bimbo-Szuhai, E.; Huniadi, A. Immunomodulatory Treatment Impact on IVF Outcomes in KIR AA Genotype: Personalized Fertility Insights. Medicina 2024, 60, 948. https://doi.org/10.3390/medicina60060948
Seles L, Zaha IA, Luncan M, Bodog A, Sachelarie L, Sandor M, Macovei IC, Bimbo-Szuhai E, Huniadi A. Immunomodulatory Treatment Impact on IVF Outcomes in KIR AA Genotype: Personalized Fertility Insights. Medicina. 2024; 60(6):948. https://doi.org/10.3390/medicina60060948
Chicago/Turabian StyleSeles, Luana, Ioana Alexandra Zaha, Mihai Luncan, Alin Bodog, Liliana Sachelarie, Mircea Sandor, Iulia Codruta Macovei, Erika Bimbo-Szuhai, and Anca Huniadi. 2024. "Immunomodulatory Treatment Impact on IVF Outcomes in KIR AA Genotype: Personalized Fertility Insights" Medicina 60, no. 6: 948. https://doi.org/10.3390/medicina60060948